Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check5 days agoChange DetectedThe page now displays a 403 Forbidden error instead of study content, signaling restricted access. A simple header and a Home link are shown.SummaryDifference18%

- Check12 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0 on the page, indicating an internal platform update. No study content or surrounding page information was modified.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page revision label changed from v3.6.5 to v3.6.6, indicating a new version of the page. It does not modify the study details, eligibility criteria, or results.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page revision updated from v3.6.4 to v3.6.5, indicating a small backend/template update rather than substantive changes to visible content.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, reflecting a minor version update to the page metadata rather than substantive changes to the study details.SummaryDifference0.0%

- Check91 days agoChange DetectedThe page shows a new revision label, updating from Revision: v3.6.0 to Revision: v3.6.3, reflecting a newer site release. This update appears to be a software revision rather than a change to the study data or page content.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.